Mostrar el registro sencillo del ítem

dc.contributor.authorWong, Kah Keng
dc.contributor.authorGascoyne, Duncan M
dc.contributor.authorSoilleux, Elizabeth J
dc.contributor.authorLyne, Linden
dc.contributor.authorSpearman, Hayley
dc.contributor.authorRoncador, Giovanna 
dc.contributor.authorPedersen, Lars M
dc.contributor.authorMøller, Michael B
dc.contributor.authorGreen, Tina M
dc.contributor.authorBanham, Alison H
dc.date.accessioned2020-07-13T16:22:45Z
dc.date.available2020-07-13T16:22:45Z
dc.date.issued2016-08-16
dc.identifier.citationOncotarget . 2016 ;7(33):52940-52956.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10750
dc.description.abstractFOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL.es_ES
dc.language.isoenges_ES
dc.publisherImpact Journals es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectTRANSCRIPTION FACTOR FOXP2;es_ES
dc.subjectCLASS-II EXPRESSIONes_ES
dc.subjectNF-KAPPA-Bes_ES
dc.subjectDOWN-REGULATIONes_ES
dc.subjectPROTEIN HIP1Res_ES
dc.subjectGENEes_ES
dc.subjectSURVIVALes_ES
dc.subjectBLIMP-1es_ES
dc.subjectDIFFERENTIATIONes_ES
dc.subjectLYMPHOCYTESes_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshAged, 80 and over es_ES
dc.subject.meshAntibodies, Monoclonal, Murine-Derived es_ES
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols es_ES
dc.subject.meshCell Line, Tumor es_ES
dc.subject.meshCyclophosphamide es_ES
dc.subject.meshDoxorubicin es_ES
dc.subject.meshFemale es_ES
dc.subject.meshForkhead Transcription Factors es_ES
dc.subject.meshGene Expression Profiling es_ES
dc.subject.meshGene Expression Regulation, Neoplastic es_ES
dc.subject.meshGene Ontology es_ES
dc.subject.meshHumans es_ES
dc.subject.meshKaplan-Meier Estimate es_ES
dc.subject.meshLymphoma, Large B-Cell, Diffuse es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshPrednisone es_ES
dc.subject.meshProtein Binding es_ES
dc.subject.meshRepressor Proteins es_ES
dc.subject.meshSignal Transduction es_ES
dc.subject.meshTranscriptome es_ES
dc.subject.meshVincristine es_ES
dc.subject.meshYoung Adult es_ES
dc.titleFOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID27224915es_ES
dc.format.volume7es_ES
dc.format.number33es_ES
dc.format.page52940-52956es_ES
dc.identifier.doi10.18632/oncotarget.9507es_ES
dc.contributor.funderUniversiti Sains Malaysia (Malasia) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1949-2553es_ES
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.9507es_ES
dc.identifier.journalOncotargetes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Anticuerpos Monoclonaleses_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional